RootsAnalysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical ContractManufacturing Services Market, 2020-2030.”
Thereport features an extensive study of the current market landscape and futureopportunities associated with the pharmaceutical contract manufacturing marketin China. The study also features a detailed analysis, highlighting thecapabilities of pharmaceutical CMOs in this region. Amongst other elements, thereport features:
· A detailed assessment of the current marketlandscape of pharmaceutical contract manufacturers in China engaged in thedevelopment of active pharmaceutical ingredients (APIs), intermediates andfinished dosage formulations (FDFs).
· A detailed landscape of the pharmaceuticalmanufacturing facilities in China, including an analysis based on location ofthese facilities, highlighting key manufacturing hubs.
· A brief discussion of various regulatoryguidelines in China and various challenges, related to regulatory scrutiny,faced by pharmaceutical manufacturers in China.
· Detailed profiles of key players that offer adiverse range of capabilities for the manufacturing of pharmaceutical productsin China.
· A review of the pharmaceutical manufacturingrelated initiatives of the top 10 big pharma players (shortlisted from the topcompanies of 2019 by revenues).
· An analysis of the partnerships andacquisitions that have been established in this domain, in the recent past.
· A detailed capacity analysis based on theinstalled reactor capacities of the manufacturing facilities in China.
· A case study comparing the keycharacteristics of large molecule and small molecule drugs, along with detailson the various steps involved in their respective manufacturing processes.
Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
Requestfor Customization:
https://www.rootsanalysis.com/reports/312/request-customization.html
KeyGeographical Regions
· Eastern China
· Southern China
· Northern China
Typeof Product
· Active Pharmaceutical Ingredients (APIs)
· Drug Products
Typeof Drug Product
· Solid
· Liquid / Semi-Solid
· Injectable
· Others
Scaleof Operation
· Clinical
· Commercial
CompanySize
· Small
· Mid-Sized
· Large / Very Large
Keyplayers covered in the report
· 2Y-Chem
· Aurisco Pharmaceutical
· ChemPartner
· Dorrapharma
· Hubei Biocause Pharmaceutical
· Infoark
· Ningbo Menovo Pharmaceutical
· Shandong Xinhua Pharmaceutical
· Shanghai Acebright Pharmaceuticals
· STA Pharmaceutical
· Zhejiang Huahai Pharmaceutical
Requestfor Sample:
https://www.rootsanalysis.com/reports/312/request-sample.html
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
PleaseVisit Our Upcoming Reports
Gonorrhea:Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
LactoseIntolerance: Pipeline Review, Developer Landscape and Competitive Insights,2021-2031
ColdChain Logistics Market, Industry Trends and Global Forecasts, 2021-2030
